Predictive value of altered p27KiP1 and p21WAF/CiP1 protein expression for the clinical prognosis of patients with localized prostate cancer

Oncology Reports

Volumn 8, Issue 6, 2001, Pages 1401-1407

  Kuczyk, M A ^a   Bokemeyer, C ^b   Hartmann, J ^b   Schubach, J ^a   Walter, C ^a   Machtens, S ^a   Knuchel R ^c   Kollmannsberger, C ^b   Jonas, U ^a   Serth, J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cell cycle; p21Waf Cip protein; p27Kip1 protein; Prognosis; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; TUMOR SUPPRESSOR PROTEIN;

ADENOCARCINOMA; AGED; ARTICLE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; SURVIVAL;

ADENOCARCINOMA; AGED; BIOLOGICAL MARKERS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0035515234     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.8.6.1401     Document Type: Article

References (32)

1. Parker SI, Tong T, Bolden S and Wingo PA: Cancer Statistics 1996. CA Cancer J Clin 46: 5-27, 1996.
2. Ackerman DA, Barry JM, Wicklund RA, Oison N and Lowe BA: Analysis of high-risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 150: 1845-1850, 1993.
3. Adolfsson J, Carstensen T and Lowhagen T: Deferred treatment in localised prostate cancer. Br J Urol 69: 183-187, 1992.
4. George NJR: Natural history of localised prostate cancer managed by conservative therapy alone. Lancet i: 494-497, 1988.
5. Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L and Krusemo UB: High 10-year survival rate in patients with early untreated prostate cancer. JAMA 267: 2191-2196, 1992.
6. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whitemore AS and Schmid HP: Localized prostate cancer: relationship of tumor volume to clinical significance for the treatment of prostate cancer. Cancer 71: 933-938, 1993.
7. Hall M, Bates S and Peters G: Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 10: 1581-1587, 1995.
8. McGarvey C and Malkovicz SB: The role of the cell cycle in genitourinary carcinoma. World J Urol 14: 310-317, 1996.
9. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
10. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y and Wang X-F: Transforming growth factor beta induces the cyclin-dependent kinase-inhibitor through a p53-independent mechanism. Proc Natl Acad Sci USA 92: 5545-5549, 1995.
11. Facher EA, Becich MJ, Deka A and Law JC: Association between human cancer and two polymorphisms occurring together within the p21WAF/Cip1 cyclin-dependent kinase inhibitor gene. Cancer 79: 2424-2429, 1997.
12. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M and Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-3385, 1997.
13. Fredersdorf S, Burns J, Milne AM, Packham G, Falls L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ and Lu X: High level expression of p27(kipl) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kipl) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380-6385, 1997.
14. Nakashima S, Natsugoe S, Matsumoto M, Kijima F, Takebayashi Y, Okumura H, Shimada M, Nakano S, Kusano C, Baba M, Takao S and Aikou T: Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res 20: 1933-1937, 2000.
15. Muller W, Grabsch H, Takeno S, Noguchi T, Hommel G and Gabbert HE: Prognostic value of the cyclin-dependent kinase inhibitor p27Kip1 in gastric cancer. Anticancer Res 20: 1787-1792, 2000.
16. Vonlanthen S, Heighway J, Kappeier A, Altermatt HJ, Borner MM and Bctticher DC: p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. Int J Oncol 16: 951-977, 2000.
17. Zirbes TK, Baldus SE, Moenig SP, Nolden S, Kunze D, Shafizadeh ST, Schneider PM, Thiele J, Hoelscher AH and Dienes HP: Prognostic impact of p21/wafl/cip1 in colorectal cancer. Int J Cancer 89: 14-18, 2000.
18. Barctton GB, Klenk U, Diebold J, Schmeller N and Lohrs U: Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21AVAF1/CIP1 expression. Br J Cancer 80: 546-555, 1999.
19. kip1) of cyclin-dependent kinase 4 activation. Cell 79: 487-496, 1994.
20. Yasui W, Kudo Y, Semba S, Yokozaki H and Tahara E: Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 88: 625-629, 1997.
21. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW and Koeffler HP: p27/Kip1 mutation found in breast cancer. Cancer Res 56: 2400-2404, 1996.
22. Ferrando AA, Balbin M, Pendas AM, Vizoso F, Velasco G and Lopez-Otin C: Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. Hum Genet 97: 91-94, 1996.
23. Ponce-Castancda MV, Lee MH, Latres E, Polyak K, Lacombe L and Montgomery K: P27 Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55: 1211-1214, 1995.
24. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D and Lieskovsky G: Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 90: 916-920, 1998.
25. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM and Wollan P: Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol 11: 324-328, 1998.
26. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, De Kernion JB, Loda M and Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941-945, 1998.
27. Fernandez PL, Arce Y, Farre X, Martinez A, Nadal A, Rey MJ, Peiro N, Campo E and Cardesa A: Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol 187: 563-566, 1999.
28. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M and Kosma VM: Prognostic value and expression of p21 (wafl/cip1) protein in prostate cancer. Prostate 39: 8-15, 1999.
29. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H and Bostwick DG: The cell cycle inhibitors p21WAF1 and p27Kip1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 6: 1896-1899, 2000.
30. Sarkar FH, Li Y, Sakr W A, Grignon DJ, Madan SS, Wood DP and Adsay V: Relationship of p21 (WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (Pea). Prostate 40: 256-260, 1999.
31. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI and Cordon-Cardo C: Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 5: 2082-2088, 1999.
32. Kuczyk M, Machtens S, Hradil K, Schubach J, Christian W, Knüchel R, Hartmann J, Bokemeyer C and Jonas U: Predictive value of decreased p27 Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 81: 1952-1958, 1999.